Shuchi Nahar's Weekend Blog!

  India's Biotechnology Industry Size, Opportunities, and Investments  Twitter Handle: @shuchi_nahar Link to my previous biotechnology blog: https://myweekendspot.blogspot.com/2021/05/biotechnology-way-towards-bio-based.html India’s Biotechnology Industry The Indian biotechnology industry amounted to US$ 63 billion in 2019 and is forecast to reach US$ 150 billion by 2025, with a CAGR of 16.4%. By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017. Bio-services, which accounted for 15% of the biotechnology industry in India, is becoming a leading destination for clinical trials, contract research, and manufacturing activities in the country. • In FY20, the sector grew 15% year on year • By FY24, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in FY18 • India has over 4237+ biotech startups and is expected to have over

Biocon Ltd. - Company Overview Twitter Handle: @shuchi_nahar Company Profile Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India established as a joint venture between Ms. Kiran Mazumdar-Shaw and Biocon Biochemicals Limited, an Ireland based multinational. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated endto-end drug discovery and development services. Biocon’s business is organized into the following reporting segments: · Sm